Discovery of Selective 17β-HSD13 Inhibitors Containing a Phenol Isostere
Journal of Medicinal Chemistry · 13.08.2026 · 69 (15) · 18938-18951
DOI: 10.1021/acs.jmedchem.6c01224 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, online erschienen am 03.08.2026. Verfasst von Cedric L Hugelshofer und 34 weiteren Autor:innen. Beteiligte Einrichtung: Merck & Co., Inc. , South San Francisco, California94080, United States. Hauptthemen laut MEDLINE: Enzyme Inhibitors, 17-Hydroxysteroid Dehydrogenases, Phenols, Drug Discovery. Die Arbeit nennt 46 Literaturangaben. Gefördert von: Merck Sharp and Dohme.
Abstract (Originalsprache)
Hydroxysteroid 17-β-dehydrogenase 13 is a liver-specific, lipid-droplet enzyme genetically linked to reduced risk of metabolic-associated steatotic liver disease (MASLD), making it a compelling therapeutic target for metabolic dysfunction–associated steatohepatitis. Herein, we describe optimization of a series of small-molecule 17β-HSD13 inhibitors originating from a carboxylic acid hit identified in a high-throughput screen. Advancement to a phenol-based series of interest showed potent biochemical activity but poor pharmacokinetic profiles. Discovery efforts focused on replacement of the metabolically liable phenol pharmacophore and led to identification of a pyrimidinone isostere demonstrating lower lipophilicity, no glucuronidation, significantly improved metabolic stability, and extended rodent plasma mean residence times. Extensive optimization of the additional vectors led to inhibitors with nanomolar cellular activity while preserving selectivity, solubility, and in vivo stability (exemplified by lead inhibitor 25). Our findings establish the pyrimidinone motif as a general phenol isostere for improving pharmacokinetic properties in 17β-HSD13 inhibitors and beyond.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Merck & Co., Inc. , South San Francisco, California94080, United States.
- Proteros Biostructures GmbH , Martinsried, Bavaria82152, Germany.
- Merck & Co., Inc. , Rahway, New Jersey07065, United States.
- Merck & Co., Inc. , West Point, Pennsylvania19486, United States.
ORCID-Profile: Cedric L Hugelshofer, Samantha E Shockley, Rebecca A Kohnz, Rimsha Mehmood, Aimie Ogawa, Yuriy Slutskyy, Ethan A Wappes, Xiujuan Wen
Förderung
- Merck Sharp and Dohme
Zitieren
APA
Hugelshofer, C. L., Stateman, L. M., Shockley, S. E., Augustin, M., Bandera, A. M., Bee, C., Choy, J. W., Chrencik, J., Ellsworth, K. P., Fincher, J., Gundersdorf, R., Johnson, J., Koglin, M., Kohnz, R. A., Lammens, A., Li, B. X., Lu, G., Mazzola, R., McCracken, A. B., …, & Jabri, S. (2026). Discovery of Selective 17β-HSD13 Inhibitors Containing a Phenol Isostere. Journal of Medicinal Chemistry, 69(15), 18938-18951. https://doi.org/10.1021/acs.jmedchem.6c01224
Vancouver
Hugelshofer CL, Stateman LM, Shockley SE, Augustin M, Bandera AM, Bee C, et al. Discovery of Selective 17β-HSD13 Inhibitors Containing a Phenol Isostere. Journal of Medicinal Chemistry. 2026;69(15):18938-18951. doi:10.1021/acs.jmedchem.6c01224
BibTeX
@article{Hugelshofer2026,
author = {Hugelshofer, Cedric L and Stateman, Leah M and Shockley, Samantha E and Augustin, Martin and Bandera, Adrian Maurice and Bee, Christine and Choy, Jonathan W and Chrencik, Jill and Ellsworth, Kenneth P and Fincher, Jarod and Gundersdorf, Richard and Johnson, Josephine and Koglin, Markus and Kohnz, Rebecca A and Lammens, Alfred and Li, Beryl X and Lu, Gang and Mazzola, Robert and McCracken, Amy B and Mehmood, Rimsha and Nizner, Peter and Novotny, Christopher and Ogawa, Aimie and Silva-Garcia, Abel and Slutskyy, Yuriy and Southgate, Emma and Sun, Zhongxiang and Tovar, Kiersten and Wappes, Ethan A and Wen, Xiujuan and Wen, Xin and Yadav, Daniela Bumbaca and Yen, Rose and Zepeda, Nancy and Jabri, Salman},
title = {Discovery of Selective 17β-HSD13 Inhibitors Containing a Phenol Isostere},
journal = {Journal of Medicinal Chemistry},
year = {2026},
volume = {69},
number = {15},
pages = {18938--18951},
doi = {10.1021/acs.jmedchem.6c01224}
}
EUVIMED